{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-155416","form_type":"8-K","ticker":"VOR","cik":"0001817229","company_name":"Vor Biopharma Inc.","filed_at":"2023-05-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.809685+00:00","generated_at":"2026-06-14T13:16:46.786575+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Vor Biopharma stockholders elect Lubner and Resnick as Class II directors, ratify EY as auditor","bullets":["David C. Lubner elected with 53,754,258 votes for, 45,048 withheld (4,500,866 broker non-votes).","Joshua Resnick, M.D. elected with 44,270,251 votes for, 9,529,055 withheld (4,500,866 broker non-votes).","Ratification of Ernst & Young as independent auditor for FY2023 approved: 58,294,758 for, 1,908 against, 3,506 abstentions.","Approximately 87% of outstanding shares (58.3M) represented at the meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-155416","json":"https://secwatch.observer/filing/0001193125-23-155416.json","markdown":"https://secwatch.observer/filing/0001193125-23-155416.md","text":"https://secwatch.observer/filing/0001193125-23-155416.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817229/000119312523155416/0001193125-23-155416-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817229/000119312523155416/d436577d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T13:16:46.786575+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ce72a8344ad37b5ea99c141fd3c92ced37f854b8","claim":"Vor Biopharma Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2023-05-26 meeting.","evidence_excerpt":"Proposal 2 – Ratification of Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023, by the following votes: Votes For Votes Against Abstentions 58,294,758 1,908 3,506","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817229/000119312523155416/0001193125-23-155416-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-26"}],"fact_type":"shareholder_vote"},{"claim_id":"f8cb3dcbcb6510a21ee5c4af1535825da98a4283","claim":"Vor Biopharma Inc. shareholders approved Election of Two Class II Directors David C. Lubner and Joshua Resnick, M.D. at the 2023-05-26 meeting.","evidence_excerpt":"by the following votes: Nominee Votes For Votes Withheld Broker Non-Votes David C. Lubner 53,754,258 45,048 4,500,866 Joshua Resnick, M.D. 44,270,251 9,529,055 4,500,866","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817229/000119312523155416/0001193125-23-155416-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-26"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}